These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 25063763)

  • 1. Successful treatment of severe thrombocytopenia with the use of thrombopoeitin receptor agonist eltrombopag in a patient with chronic myelomonocytic leukemia.
    Modi Y; Shaaban H; Gauchan D; Maroules M
    J Oncol Pharm Pract; 2015 Feb; 21(1):74-5. PubMed ID: 25063763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eltrombopag for myelodysplastic syndromes or chronic myelomonocytic leukaemia with no excess blasts and thrombocytopenia: a French multicentre retrospective real-life study.
    Comont T; Meunier M; Cherait A; Santana C; Cluzeau T; Slama B; Laribi K; Giraud JT; Dimicoli S; Berceanu A; Le Clech L; Cony-Makhoul P; Gruson B; Torregrosa J; Sanhes L; Jachiet V; Azerad MA; Al Jijakli A; Gyan E; Gaudin C; Broner J; Guerveno C; Guillaume T; Ades PL; Beyne-Rauzy O; Fenaux P;
    Br J Haematol; 2021 Jul; 194(2):336-343. PubMed ID: 34151423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful eltrombopag treatment of severe refractory thrombocytopenia in chronic myelomonocytic leukemia: Two cases reports: A CARE-compliant article.
    Gao Y; Gong M; Zhang C; Kong X; Ma Y
    Medicine (Baltimore); 2017 Oct; 96(43):e8337. PubMed ID: 29069007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful platelet count recovery in lupus-associated thrombocytopenia with the thrombopoietin agonist eltrombopag.
    Scheinberg P; Singulane CC; Barbosa LS; Scheinberg M
    Clin Rheumatol; 2014 Sep; 33(9):1347-9. PubMed ID: 24740463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eltrombopag Use in Patients With Chronic Myelomonocytic Leukemia (CMML): A Cautionary Tale.
    Ramadan H; Duong VH; Al Ali N; Padron E; Zhang L; Lancet JE; List AF; Komrokji RS
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S64-6. PubMed ID: 27521328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Eltrombopag for the treatment of thrombocytopenia in patients with chronic hepatitis C: two case reports].
    Guglieri-López B; Ventura-Cerdá JM; Carmena-Carmena J; Climente-Mónica M
    Farm Hosp; 2013; 37(5):419-21. PubMed ID: 24128106
    [No Abstract]   [Full Text] [Related]  

  • 7. Use of eltrombopag for the treatment of thrombocytopenia in hypoplastic myelodysplastic syndrome.
    Gauchan D; Shaaban H; Gedeon D; Maroules M
    Ann Hematol; 2014 Oct; 93(10):1777-8. PubMed ID: 24554304
    [No Abstract]   [Full Text] [Related]  

  • 8. Eltrombopag fails to improve severe thrombocytopenia in late-stage dyskeratosis congenita and diamond-blackfan-anaemia.
    Trautmann K; Jakob C; von Grünhagen U; Schleyer E; Brümmendorf TH; Siegert G; Ehninger G; Platzbecker U
    Thromb Haemost; 2012 Aug; 108(2):397-8. PubMed ID: 22739569
    [No Abstract]   [Full Text] [Related]  

  • 9. Eltrombopag for resistant immune thrombocytopenia secondary to chronic lymphocytic leukaemia.
    Jolliffe E; Romeril K
    Intern Med J; 2014 Jul; 44(7):697-9. PubMed ID: 25041772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usage of eltrombopag for chronic immune thrombocytopenia as a pretreatment for splenectomy.
    Uwagawa T; Misawa T; Furukawa K; Ito R; Futagawa Y; Yahagi Y; Aiba K; Yanaga K
    Acta Haematol; 2013; 129(1):45-7. PubMed ID: 23128016
    [No Abstract]   [Full Text] [Related]  

  • 11. Eltrombopag in thrombocytopenia.
    Lawson A
    N Engl J Med; 2008 Mar; 358(10):1072; author reply 1072-3. PubMed ID: 18322290
    [No Abstract]   [Full Text] [Related]  

  • 12. Eltrombopag for the treatment of immune thrombocytopenia.
    Cheng G
    Expert Rev Hematol; 2011 Jun; 4(3):261-9. PubMed ID: 21671710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.
    Oliva EN; Alati C; Santini V; Poloni A; Molteni A; Niscola P; Salvi F; Sanpaolo G; Balleari E; Germing U; Fenaux P; Stamatoullas A; Palumbo GA; Salutari P; Impera S; Avanzini P; Cortelezzi A; Liberati AM; Carluccio P; Buccisano F; Voso MT; Mancini S; Kulasekararaj A; Morabito F; Bocchia M; Cufari P; Spiriti MA; Santacaterina I; D'Errigo MG; Bova I; Zini G; Latagliata R
    Lancet Haematol; 2017 Mar; 4(3):e127-e136. PubMed ID: 28162984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of eltrombopag, a thrombopoietin receptor agonist, in post-transplantation thrombocytopenia.
    Reid R; Bennett JM; Becker M; Chen Y; Milner L; Phillips GL; Liesveld J
    Am J Hematol; 2012 Jul; 87(7):743-5. PubMed ID: 22573520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eltrombopag for treatment of thrombocytopenia-associated disorders.
    Merli P; Strocchio L; Vinti L; Palumbo G; Locatelli F
    Expert Opin Pharmacother; 2015; 16(14):2243-56. PubMed ID: 26364898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C.
    McHutchison JG; Dusheiko G; Shiffman ML; Rodriguez-Torres M; Sigal S; Bourliere M; Berg T; Gordon SC; Campbell FM; Theodore D; Blackman N; Jenkins J; Afdhal NH;
    N Engl J Med; 2007 Nov; 357(22):2227-36. PubMed ID: 18046027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Development of myelofibrosis during eltrombopag treatment in a patient with immune thrombocytopenia].
    Horikoshi A; Tsukuda J; Abe R; Fujiwara N; Ito E; Takaku T
    Rinsho Ketsueki; 2016 May; 57(5):638-41. PubMed ID: 27263792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune thrombocytopenic purpura--from agony to agonist.
    Schwartz RS
    N Engl J Med; 2007 Nov; 357(22):2299-301. PubMed ID: 18046034
    [No Abstract]   [Full Text] [Related]  

  • 19. Eltrombopag--an oral thrombopoietin agonist.
    Sharma V; Randhawa H; Sharma A; Aggarwal S
    Eur Rev Med Pharmacol Sci; 2012 Jun; 16(6):743-6. PubMed ID: 22913204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study.
    Cheng G; Saleh MN; Marcher C; Vasey S; Mayer B; Aivado M; Arning M; Stone NL; Bussel JB
    Lancet; 2011 Jan; 377(9763):393-402. PubMed ID: 20739054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.